Questions about MS? Call us on 0808 800 8000

Caitlin Astbury


Caitlin Astbury was our Research Communications Officer.

Blogs by Caitlin Astbury

The journey of a drug

It takes a long time and lots of hard work to develop a new MS treatment. In 2019, ocrelizumab (brand name Ocrevus) became the first drug to be available for people with primary progressive MS on the NHS.

The clinical trials taking us closer to stopping MS

To help people at every stage of MS, we need to stop MS from progressing. Researchers are looking at three ways to do this. And we’ve now reached the point where there are clinical trials in progress for all three.

Myelin repair research goes virtual

This year, many MS researchers have found themselves working from home. But that doesn’t mean they’re working alone. The world’s two biggest MS research conferences have joined forces to go virtual, giving researchers like Dr Veronique Miron from the University of Edinburgh the vital opportunity to share their results and collaborate.

New ways to manage cognitive symptoms in MS

We know around half of all people with MS experience problems with cognitive processes. Researchers are working hard to understand more about how we can help people to manage cognitive symptoms of MS.

Progress on progressive MS

We're funding world-class research into new treatments and improved care and services for people with progressive MS.

Behind the headlines: can a vaccine stop MS?

You may have seen the suggestion that a vaccination for a common virus could stop MS. We look behind the headlines to see what the original research actually said. A recent paper suggests that MS could be caused by threadworms and Epstein-Barr virus – two common infections. But researchers didn’t present any new evidence and are just proposing it as an idea.